NCT00002213View on ClinicalTrials.gov

The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Efavirenz

Trial Locations (9)

10011

Saint Vincents Hosp / AIDS Ctr / 4th Floor, New York

20892

Niaid / Nih, Bethesda

27499

Univ of North Carolina Chapel Hill, Chapel Hill

45267

Univ Int Med Assoc Inc / Holmes Hosp / U of Cincinnati, Cincinnati

60611

Northwestern Univ Med School AIDS Treatment Unit, Chicago

90036

Kraus Med Partners, Los Angeles

94705

East Bay AIDS Ctr, Berkeley

02215

Beth Israel Deaconess Med Ctr, Boston

02906

The Miriam Hosp, Providence

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002213 - The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors | Biotech Hunter | Biotech Hunter